NOVO NORDISK CFO: IF CATALENT DEAL DOES NOT CLOSE, MORE CAPEX WILL BE NEEDED TO BUILD FILL-FINISH CAPACITY INTERNALLY
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
903.3 DKK | -1.05% | +2.28% | +29.39% |
12:08pm | Arecor Therapeutics' Investigational Insulin Shows Fast Absorption in Early-stage Study | MT |
06:01am | Genetic profile may predict best response to weight-loss drug Wegovy | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.39% | 584B | |
+32.09% | 693B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+13.89% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B | |
-0.52% | 162B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk Cfo: If Catalent Deal Does Not Close, More Capex W…